Article ; Online: Update on Lung Transplantation for Cystic Fibrosis.
2022 Volume 43, Issue 4, Page(s) 821–840
Abstract: Lung transplantation provides a treatment option for many individuals with advanced lung disease due to cystic fibrosis (CF). Since the first transplants for CF in the 1980s, survival has improved and the opportunity for transplant has expanded to ... ...
| Abstract | Lung transplantation provides a treatment option for many individuals with advanced lung disease due to cystic fibrosis (CF). Since the first transplants for CF in the 1980s, survival has improved and the opportunity for transplant has expanded to include individuals who previously were not considered candidates for transplant. Criteria to be a transplant candidate vary significantly among transplant programs, highlighting that the engagement in more than one transplant program may be necessary. Individuals with highly resistant CF pathogens, malnutrition, osteoporosis, CF liver disease, and other comorbidities may be suitable candidates for lung transplant, or if needed, multi-organ transplant. The transplant process involves several phases, from discussion of prognosis and referral to a transplant center, to transplant evaluation, to listing, transplant surgery, and care after transplant. While the availability of highly effective CF transmembrane conductance regulator (CFTR) modulators for many individuals with CF has improved lung function and slowed progression to respiratory failure, early discussion regarding transplant as a treatment option and referral to a transplant program are critical to maximizing opportunity and optimizing patient and family experience. The decision to be evaluated for transplant and to list for transplant are distinct, and early referral may provide a treatment option that can be urgently executed if needed. Survival after transplant for CF is improving, to a median survival of approximately 10 years, and most transplant survivors enjoy significant improvement in quality of life. |
|---|---|
| MeSH term(s) | Humans ; Cystic Fibrosis/complications ; Cystic Fibrosis/surgery ; Quality of Life ; Cystic Fibrosis Transmembrane Conductance Regulator ; Lung Transplantation ; Lung ; Respiratory Insufficiency |
| Chemical Substances | Cystic Fibrosis Transmembrane Conductance Regulator (126880-72-6) |
| Language | English |
| Publishing date | 2022-11-04 |
| Publishing country | United States |
| Document type | Journal Article ; Review |
| ZDB-ID | 447455-7 |
| ISSN | 1557-8216 ; 0272-5231 |
| ISSN (online) | 1557-8216 |
| ISSN | 0272-5231 |
| DOI | 10.1016/j.ccm.2022.07.002 |
| Database | MEDical Literature Analysis and Retrieval System OnLINE |
More links
Kategorien
In stock of ZB MED Cologne/Königswinter
| Se 805: Show issues | Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular ab Jg. 2022: Lesesaal (EG) |
Order via subito
This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.